ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
